Elicio Therapeutics, Inc.ELTXNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank11
3Y CAGR-7.1%
5Y CAGR-14.2%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
-7.1%/yr
vs +29.1%/yr prior
5Y CAGR
-14.2%/yr
Recent acceleration
Acceleration
-36.3pp
Decelerating
Percentile
P11
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $847000.00 | -28.1% |
| 2024 | $1.18M | +0.7% |
| 2023 | $1.17M | +10.7% |
| 2022 | $1.06M | -14.3% |
| 2021 | $1.23M | -32.1% |
| 2020 | $1.82M | +60.0% |
| 2019 | $1.14M | +198.9% |
| 2018 | $380000.00 | -88.0% |
| 2013 | $3.17M | -13.6% |
| 2012 | $3.67M | - |